This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

Anaeropharma Science Initiates First-in-Human Trial Of Novel Recombinant Bifidobacterial Anti-cancer Agent APS001F For Advanced Solid Tumors

 



TOKYO, March 28, 2013 /PRNewswire/ -- Anaeropharma Science Inc. announced on March 28 that it has initiated a Phase I clinical trial of APS001F in patients with advanced solid tumors in the United States. The first-in-human dose-escalation trial enrolls patients with advanced and/or metastatic solid tumors whose disease is no longer considered responsive to available treatments. The trial is designed to evaluate safety, tolerability and efficacy of the study agent.

About APS001FAPS001F is a living recombinant bifidobacterium to express the cytosine deaminase (CD) gene. Bifidobacterium is a non-pathogenic obligate anaerobe and a major component of normal human intestinal flora. It is well-known that the majority of human solid tumors contain hypoxic regions, mainly due to insufficient vascular formation. When APS001F is administered intravenously, APS001F localizes and grows in the hypoxic regions of tumors, which results in expression of the CD enzyme in tumors. 5-FC, a commercially available anti-fungal agent, which is administered orally, is converted to 5-FU, an active anti-tumor agent, by the CD enzyme expressed by APS001F in tumors. The novel therapy is expected to have the advantage of limiting the systemic toxicity of 5-FU due to the local formation of 5-FU in tumors. It also allows 5-FU to achieve high concentration in tumors, which results in clear anti-tumor efficacy.

About Tumor HypoxiaThe majority of human solid tumors contain regions of acute or chronic hypoxia, mainly due to insufficient and unusual angiogenesis. Tumor hypoxia is a prognostic factor, commonly associated with aggressive tumor growth and poor survival rate. These microenvironments cause decreased uptake of chemotherapeutic drugs. Though many drugs and technologies exploiting tumor hypoxia have been explored in clinical trials, no effective anti-cancer drugs or methods based on tumor hypoxia have been developed to date. A critical factor in the success of this strategy is the need to develop adequate delivery of anti-cancer drugs targeting regions of tumor hypoxia. APS001F has great potential to achieve adequate delivery of the objective anti-cancer drug.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,214.42 -10.15 -0.06%
S&P 500 2,110.74 -3.12 -0.15%
NASDAQ 4,987.89 +20.7530 0.42%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs